Updated DepMap data to "Public 18Q2" Release:
- Avana CRISPR screen dataset expanded to include 436 cell lines.
- Mutation, indel, copy number and gene expression data also expanded to include new lines in Avana dataset.
Added Combined Broad, Novartis, Marcotte et al. RNAi data: 713 unique cell lines screened across three large-scale RNAi datasets, with integrated gene dependencies estimated using the DEMETER2 algorithm.Update (2018/06/21)
Corrected incorrect copy number data which was shown for some cell lines. View datasets
Use this portal to:
UNDERSTAND Dependency profiles at genome-scale across more than 500 human cell lines
FIND Detailed genetic and pharmacologic characterization of over 1000 cell lines
IDENTIFY Genetic drivers that have functional importance as potential drug targets
SEARCH For cell line models that best represent your research interests
EXPORT Presentation-quality figures
The goal of the Cancer Dependency Map is to create a comprehensive preclinical reference map connecting tumor features with tumor dependencies to accelerate the development of precision treatments. Our strategy is to systematically characterize cellular models of cancers and to test those models for sensitivity to genetic and small-molecule perturbations. By integrating data beyond those collected at the Broad, DepMap hopes to develop a complete understanding of the vulnerabilities of cancer, identify targets for therapeutic development, and design strategies to optimize patient responses to those therapies.
To date DepMap has profiled more than 500 cell lines. Over the next several years we will greatly expand the diversity of cell lines profiled for genetic vulnerabilities with quarterly data release. Additionally, limited drug sensitivity data are available.